PMID- 29500148
OWN - NLM
STAT- MEDLINE
DCOM- 20190523
LR  - 20190523
IS  - 2152-2669 (Electronic)
IS  - 2152-2669 (Linking)
VI  - 18
IP  - 4
DP  - 2018 Apr
TI  - Thiotepa, Etoposide, Cyclophosphamide, Cytarabine, and Melphalan (TECAM) 
      Conditioning Regimen for Autologous Stem Cell Transplantation in Lymphoma.
PG  - 272-279
LID - S2152-2650(17)31849-9 [pii]
LID - 10.1016/j.clml.2018.02.008 [doi]
AB  - BACKGROUND: High-dose chemotherapy and autologous stem cell transplantation 
      (ASCT) is the current standard of care for relapsed non-Hodgkin lymphoma (NHL) 
      and Hodgkin lymphoma (HL). Conditioning regimens with high-dose carmustine have 
      been associated with idiopathic pneumonitis syndrome. We, therefore, created a 
      modified alternative TECAM conditioning regimen, consisting of etoposide, 
      thiotepa, cytarabine, cyclophosphamide, and melphalan. PATIENTS AND METHODS: We 
      retrospectively analyzed our cohort of 212 NHL and HL patients, who had undergone 
      ASCT with the TECAM conditioning regimen from 2000 to 2013. Although toxicity and 
      engraftment were analyzed for all 212 patients, the survival analysis was 
      performed for the 2 largest groups of patients, those with diffuse large B-cell 
      lymphoma (DLBCL) and those with HL (n = 127) to minimize heterogeneity. RESULTS: 
      The 3-year overall survival among the DLBCL and HL patients was 0.618 (95% 
      confidence interval [CI], 0.490-0.722) and 0.828 (95% CI, 0.701-0.904), 
      respectively. Stage IV disease at transplantation was a statistically significant 
      poor prognostic factor. Higher Eastern Cooperative Oncology Group performance 
      status and progressive disease at transplantation were found to be borderline 
      significant. No idiopathic pneumonitis syndrome cases were reported in our 
      cohort. Six patients died of treatment-related toxicity during the first 100 
      days. The 3-year progression-free survival was 0.5 (95% CI, 0.37-0.61) for HL 
      patients and 0.49 (95% CI, 0.36-0.60) for DLBCL patients. CONCLUSION: Our results 
      are encouraging and justify evaluation of TECAM versus BEAM (carmustine, 
      etoposide, cytarabine, melphalan) in a prospective multicenter study in a large 
      homogenous patient population.
CI  - Copyright (c) 2018 Elsevier Inc. All rights reserved.
FAU - Grisariu, Sigal
AU  - Grisariu S
AD  - Department of Bone Marrow Transplantation and Cancer Immunotherapy, 
      Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
FAU - Shapira, Michael Y
AU  - Shapira MY
AD  - Department of Bone Marrow Transplantation and Cancer Immunotherapy, 
      Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
FAU - Or, Reuven
AU  - Or R
AD  - Department of Bone Marrow Transplantation and Cancer Immunotherapy, 
      Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
FAU - Avni, Batia
AU  - Avni B
AD  - Department of Bone Marrow Transplantation and Cancer Immunotherapy, 
      Hadassah-Hebrew University Medical Center, Jerusalem, Israel. Electronic address: 
      batiaa@hadassah.org.il.
LA  - eng
PT  - Journal Article
DEP - 20180215
PL  - United States
TA  - Clin Lymphoma Myeloma Leuk
JT  - Clinical lymphoma, myeloma & leukemia
JID - 101525386
RN  - 04079A1RDZ (Cytarabine)
RN  - 6PLQ3CP4P3 (Etoposide)
RN  - 8N3DW7272P (Cyclophosphamide)
RN  - 905Z5W3GKH (Thiotepa)
RN  - Q41OR9510P (Melphalan)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Cyclophosphamide/administration & dosage/adverse effects
MH  - Cytarabine/administration & dosage/adverse effects
MH  - Etoposide/administration & dosage/adverse effects
MH  - Female
MH  - Hematopoietic Stem Cell Transplantation/*methods/mortality
MH  - Hodgkin Disease/mortality/*therapy
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Male
MH  - Melphalan/administration & dosage/adverse effects
MH  - Middle Aged
MH  - Pneumonia/chemically induced/prevention & control
MH  - Retrospective Studies
MH  - Thiotepa/administration & dosage/adverse effects
MH  - Transplantation Conditioning/adverse effects/*methods/mortality
MH  - Transplantation, Autologous/methods
MH  - Young Adult
OTO - NOTNLM
OT  - Autologous stem cell transplantation
OT  - Conditioning regimen
OT  - Idiopathic pneumonitis syndrome
OT  - Lymphoma
OT  - TECAM
EDAT- 2018/03/04 06:00
MHDA- 2019/05/24 06:00
CRDT- 2018/03/04 06:00
PHST- 2017/11/19 00:00 [received]
PHST- 2018/01/16 00:00 [revised]
PHST- 2018/02/10 00:00 [accepted]
PHST- 2018/03/04 06:00 [pubmed]
PHST- 2019/05/24 06:00 [medline]
PHST- 2018/03/04 06:00 [entrez]
AID - S2152-2650(17)31849-9 [pii]
AID - 10.1016/j.clml.2018.02.008 [doi]
PST - ppublish
SO  - Clin Lymphoma Myeloma Leuk. 2018 Apr;18(4):272-279. doi: 
      10.1016/j.clml.2018.02.008. Epub 2018 Feb 15.